DuChemBIO Co.,Ltd.

A176750

KR7176750008

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 03:30:00 03/07/2024 am IST			5-day change	1st Jan Change
11,290 ^KRW	+6.21%		+9.19%	+105.27%

2020	Telix Pharmaceuticals Limited Enters into A Commercialisation and Partnership Agreement with Duchembio Co, Ltd	CI
2020	Radiopharmaceutical Business Division of CareCamp Inc. agreed to acquire DuChemBIO Co.,Ltd. from Kim Jong-woo and others, in a reverse merger transaction for approximately KRW 210 billion.	CI

DuChemBIO Co.,Ltd. announced that it has received KRW 4.5 billion in funding from RNR Partners Group Co., Ltd., YNK Company Inc.

September 29, 2020

On September 29, 2020, DuChemBIO Co.,Ltd. (XKON:A176750) closed the transaction.

Latest news about DuChemBIO Co.,Ltd.

Telix Pharmaceuticals Limited Enters into A Commercialisation and Partnership Agreement with Duchembio Co, Ltd	03/20/03	CI
Radiopharmaceutical Business Division of CareCamp Inc. agreed to acquire DuChemBIO Co.,Ltd. from Kim Jong-woo and others, in a reverse merger transaction for approximately KRW 210 billion.	24/20/24	CI
DuChemBIO Co.,Ltd. announced that it has received KRW 4.5 billion in funding from RNR Partners Group Co., Ltd., YNK Company Inc.	29/20/29	CI
DuChemBIO Co.,Ltd. announced that it expects to receive KRW 4.5 billion in funding from RNR Partners Group Co., Ltd., YNK Company Inc.	23/20/23	CI
ITM Isotopen Technologien München and DuChemBio Sign Exclusive Licensing & Development Agreement for Solucin® TRT in South Korea	02/19/02	CI
DuChemBIO Co.,Ltd. announced that it has received KRW 5.37897425 billion in funding from Korea Investment & Securities Co., Ltd., Investment Arm, Samsung Securities Co.,Ltd., Korea Development Bank, Investment Arm, Komelon Corporation	26/19/26	CI
DuChemBIO Co.,Ltd. announced that it expects to receive KRW 5.37897425 billion in funding from Korea Investment & Securities Co., Ltd., Investment Arm, Samsung Securities Co.,Ltd., Korea Development Bank, Investment Arm, Komelon Corporation	18/19/18	CI
DuChemBIO Co.,Ltd. announced that it has received KRW 2.99996 billion in funding	19/18/19	CI
DuChemBIO Co.,Ltd. announced that it expects to receive KRW 2.99996 billion in funding	11/18/11	CI
DuChemBIO Co.,Ltd. announced that it has received KRW 999.994 million in funding from Korea Investment & Securities Co., Ltd., Investment Arm	02/18/02	CI
DuChemBIO Co.,Ltd. announced that it expects to receive KRW 999.994 million in funding from Korea Investment & Securities Co., Ltd., Investment Arm	19/18/19	CI
DuChemBIO Co.,Ltd. announced that it has received KRW 1.299994 billion in funding from NH Investment & Securities Co., Ltd., Investment Arm	21/18/21	CI
DuChemBIO Co.,Ltd. announced that it expects to receive KRW 1.299994 billion in funding from NH Investment & Securities Co., Ltd., Investment Arm	13/18/13	CI
DuChemBIO Co.,Ltd. announced that it has received KRW 3 billion in funding	13/18/13	CI
DuChemBIO Co.,Ltd. announced that it expects to receive KRW 3 billion in funding	05/18/05	CI
DuChemBIO Co.,Ltd. announced that it has received KRW 2 billion in funding from Asam Asset Management Co., Ltd., Korea Investment & Securities Co., Ltd., Investment Arm	12/18/12	CI
DuChemBio Co., Ltd. announced that it has received KRW 3 billion in funding.	28/15/28	CI
DuChemBio Co., Ltd. announced that it expects to receive KRW 3 billion in funding.	27/15/27	CI
DuChemBio Co., Ltd. announced that it has received KRW 2 billion in funding from Mega Investment Co., Ltd., ASAM Investment Advisory Company Limited.	18/15/18	CI
Duchem Bio Co., Ltd. announced that it expects to receive KRW 2 billion in funding from Mega Investment Co., Ltd., ASAM Investment Advisory Company Limited, and another investor.	12/15/12	CI

DuChemBio Co Ltd is a Korea-based company principally engaged in the manufacture and sale of radiopharmaceuticals. The Company is engaged in the manufacture and sale of diagnostic radiopharmaceuticals such as radiopharmaceuticals for the diagnosis of Parkinson's disease, radiopharmaceuticals for the diagnosis of Alzheimer's disease, and radiopharmaceuticals for the diagnosis of brain tumors. In addition, the Company is engaged in the sale of computed tomography (CT) contrast agents and other products.

Sector

Pharmaceuticals

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
DUCHEMBIO CO.,LTD.	+105.27%	207M
ELI LILLY AND COMPANY	+54.07%	816B
NOVO NORDISK A/S	+38.59%	634B
JOHNSON & JOHNSON	-7.05%	351B
MERCK & CO., INC.	+15.44%	323B
ABBVIE INC.	+5.72%	293B
ASTRAZENECA PLC	+13.40%	238B
ROCHE HOLDING AG	+0.61%	222B
NOVARTIS AG	+13.24%	218B
AMGEN INC.	+7.42%	167B

Other Pharmaceuticals

DuChemBIO Co.,Ltd.

Equities

A176750

KR7176750008

Pharmaceuticals

DuChemBIO Co.,Ltd. announced that it has received KRW 4.5 billion in funding from RNR Partners Group Co., Ltd., YNK Company Inc.

Latest news about DuChemBIO Co.,Ltd.

Chart DuChemBIO Co.,Ltd.

Company Profile

Sector Other Pharmaceuticals